Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 26 | 2018 | 700 | 1.880 |
Why?
|
| Brain Ischemia | 12 | 2012 | 160 | 1.210 |
Why?
|
| Thrombolytic Therapy | 10 | 2012 | 67 | 1.000 |
Why?
|
| Cerebral Hemorrhage | 11 | 2021 | 72 | 0.940 |
Why?
|
| Tissue Plasminogen Activator | 7 | 2012 | 46 | 0.860 |
Why?
|
| Cerebral Infarction | 6 | 2012 | 25 | 0.780 |
Why?
|
| Fibrinolytic Agents | 9 | 2018 | 71 | 0.690 |
Why?
|
| Vasospasm, Intracranial | 4 | 2014 | 13 | 0.650 |
Why?
|
| Hypertension | 8 | 2018 | 1024 | 0.650 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2014 | 25 | 0.650 |
Why?
|
| Basal Ganglia Hemorrhage | 1 | 2018 | 1 | 0.590 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2012 | 986 | 0.580 |
Why?
|
| Diskectomy | 1 | 2018 | 18 | 0.580 |
Why?
|
| Spinal Stenosis | 1 | 2018 | 10 | 0.580 |
Why?
|
| Antihypertensive Agents | 6 | 2018 | 378 | 0.460 |
Why?
|
| Intracranial Aneurysm | 2 | 2014 | 68 | 0.440 |
Why?
|
| Nervous System Diseases | 2 | 2012 | 47 | 0.440 |
Why?
|
| Carotid Artery, Internal | 2 | 2014 | 33 | 0.440 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2012 | 1387 | 0.440 |
Why?
|
| Infarction, Middle Cerebral Artery | 3 | 2011 | 16 | 0.430 |
Why?
|
| Aged, 80 and over | 20 | 2018 | 4152 | 0.400 |
Why?
|
| Humans | 52 | 2021 | 34497 | 0.380 |
Why?
|
| Aged | 36 | 2018 | 11002 | 0.370 |
Why?
|
| Middle Aged | 31 | 2021 | 12707 | 0.370 |
Why?
|
| Reperfusion Injury | 1 | 2012 | 58 | 0.360 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2011 | 1 | 0.350 |
Why?
|
| Seizures | 2 | 2009 | 67 | 0.350 |
Why?
|
| Aneurysm, Dissecting | 1 | 2011 | 13 | 0.350 |
Why?
|
| Argon | 1 | 2011 | 2 | 0.350 |
Why?
|
| Xenon | 1 | 2011 | 3 | 0.350 |
Why?
|
| Diagnostic Imaging | 2 | 2009 | 101 | 0.340 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 34 | 0.340 |
Why?
|
| Intracranial Hemorrhage, Hypertensive | 2 | 2010 | 4 | 0.330 |
Why?
|
| Angioplasty | 4 | 2018 | 31 | 0.330 |
Why?
|
| Female | 38 | 2018 | 21499 | 0.320 |
Why?
|
| Blood Pressure | 4 | 2012 | 901 | 0.320 |
Why?
|
| Male | 37 | 2018 | 20713 | 0.300 |
Why?
|
| Retrospective Studies | 13 | 2021 | 3814 | 0.290 |
Why?
|
| Carotid Stenosis | 3 | 2018 | 61 | 0.280 |
Why?
|
| Brain | 7 | 2010 | 1031 | 0.260 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2008 | 94 | 0.260 |
Why?
|
| Peptides | 1 | 2008 | 142 | 0.260 |
Why?
|
| Treatment Outcome | 14 | 2018 | 3618 | 0.240 |
Why?
|
| Acute Disease | 6 | 2012 | 276 | 0.220 |
Why?
|
| Hematoma | 2 | 2017 | 27 | 0.220 |
Why?
|
| Hyperglycemia | 2 | 2017 | 88 | 0.210 |
Why?
|
| Adult | 18 | 2018 | 10019 | 0.210 |
Why?
|
| Hospitalization | 4 | 2011 | 500 | 0.210 |
Why?
|
| Intracranial Embolism | 2 | 2001 | 15 | 0.200 |
Why?
|
| Stents | 2 | 2018 | 167 | 0.200 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 31 | 0.170 |
Why?
|
| Embolism, Cholesterol | 1 | 2000 | 6 | 0.160 |
Why?
|
| United States | 8 | 2012 | 4267 | 0.160 |
Why?
|
| Headache | 1 | 2019 | 78 | 0.150 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 54 | 0.150 |
Why?
|
| Cervical Vertebrae | 1 | 2018 | 54 | 0.140 |
Why?
|
| Angioplasty, Balloon | 2 | 2010 | 33 | 0.140 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 30 | 0.140 |
Why?
|
| Brain Infarction | 2 | 2011 | 10 | 0.130 |
Why?
|
| Thrombectomy | 1 | 2018 | 75 | 0.130 |
Why?
|
| Pilot Projects | 5 | 2018 | 584 | 0.130 |
Why?
|
| Telemedicine | 1 | 2018 | 120 | 0.120 |
Why?
|
| Risk Factors | 6 | 2021 | 4136 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 2366 | 0.120 |
Why?
|
| Prevalence | 4 | 2012 | 1034 | 0.120 |
Why?
|
| Blood Flow Velocity | 2 | 2014 | 87 | 0.120 |
Why?
|
| Nicardipine | 3 | 2011 | 5 | 0.120 |
Why?
|
| Brain Edema | 2 | 2011 | 16 | 0.110 |
Why?
|
| Reperfusion | 2 | 2012 | 21 | 0.110 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 13 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2008 | 168 | 0.110 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2014 | 34 | 0.110 |
Why?
|
| Infusions, Intravenous | 3 | 2011 | 110 | 0.110 |
Why?
|
| Prognosis | 4 | 2012 | 1603 | 0.100 |
Why?
|
| Blood Glucose | 2 | 2017 | 529 | 0.100 |
Why?
|
| Double-Blind Method | 2 | 2012 | 597 | 0.100 |
Why?
|
| Recombinant Proteins | 3 | 2011 | 281 | 0.100 |
Why?
|
| Emergency Service, Hospital | 3 | 2008 | 502 | 0.100 |
Why?
|
| Placebo Effect | 1 | 2012 | 18 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 4 | 2007 | 56 | 0.090 |
Why?
|
| Neoplasms | 1 | 2019 | 791 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 922 | 0.090 |
Why?
|
| Chi-Square Distribution | 5 | 2011 | 304 | 0.080 |
Why?
|
| Cerebral Angiography | 2 | 2008 | 60 | 0.080 |
Why?
|
| Patient Selection | 1 | 2012 | 291 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2011 | 141 | 0.080 |
Why?
|
| Prospective Studies | 7 | 2012 | 2461 | 0.080 |
Why?
|
| Medicare | 1 | 2011 | 217 | 0.080 |
Why?
|
| Carotid Arteries | 1 | 2010 | 116 | 0.080 |
Why?
|
| Nitroprusside | 1 | 2009 | 5 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 4 | 2007 | 104 | 0.070 |
Why?
|
| Emergency Medical Services | 2 | 2010 | 189 | 0.070 |
Why?
|
| Dehydration | 1 | 2008 | 9 | 0.070 |
Why?
|
| Drinking | 1 | 2008 | 10 | 0.070 |
Why?
|
| Hypovolemia | 1 | 2008 | 3 | 0.070 |
Why?
|
| Phenylephrine | 2 | 2006 | 35 | 0.070 |
Why?
|
| Logistic Models | 5 | 2011 | 808 | 0.070 |
Why?
|
| Time Factors | 5 | 2010 | 2352 | 0.070 |
Why?
|
| Young Adult | 2 | 2012 | 2827 | 0.070 |
Why?
|
| Injections, Intra-Arterial | 1 | 2008 | 7 | 0.070 |
Why?
|
| Mass Screening | 2 | 2008 | 268 | 0.070 |
Why?
|
| Predictive Value of Tests | 4 | 2004 | 934 | 0.070 |
Why?
|
| Hospital Charges | 1 | 2007 | 16 | 0.070 |
Why?
|
| Moyamoya Disease | 1 | 2007 | 1 | 0.060 |
Why?
|
| Length of Stay | 4 | 2011 | 335 | 0.060 |
Why?
|
| Intracranial Pressure | 1 | 2006 | 17 | 0.060 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 95 | 0.060 |
Why?
|
| Epinephrine | 1 | 2006 | 45 | 0.060 |
Why?
|
| Middle Cerebral Artery | 1 | 2006 | 13 | 0.060 |
Why?
|
| Embolization, Therapeutic | 2 | 2011 | 86 | 0.060 |
Why?
|
| Norepinephrine | 1 | 2006 | 103 | 0.060 |
Why?
|
| Homeostasis | 1 | 2006 | 137 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2006 | 167 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 565 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2004 | 16 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2004 | 52 | 0.050 |
Why?
|
| Troponin I | 1 | 2004 | 25 | 0.050 |
Why?
|
| Animals | 2 | 2017 | 8544 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 429 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2003 | 12 | 0.050 |
Why?
|
| Survival Rate | 3 | 2011 | 925 | 0.050 |
Why?
|
| Insulin | 2 | 2017 | 394 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2003 | 130 | 0.050 |
Why?
|
| Contrast Media | 1 | 2002 | 148 | 0.040 |
Why?
|
| Fever | 1 | 2001 | 63 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2001 | 38 | 0.040 |
Why?
|
| Aortic Aneurysm | 1 | 2000 | 14 | 0.040 |
Why?
|
| Autopsy | 1 | 2000 | 38 | 0.040 |
Why?
|
| Glasgow Coma Scale | 2 | 2011 | 28 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2000 | 58 | 0.040 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2019 | 18 | 0.040 |
Why?
|
| Heart Failure | 1 | 2007 | 780 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 819 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2019 | 70 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 118 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 29 | 0.040 |
Why?
|
| Iodine | 1 | 2017 | 6 | 0.030 |
Why?
|
| Calibration | 1 | 2017 | 30 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2011 | 325 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 73 | 0.030 |
Why?
|
| Hospital Mortality | 2 | 2009 | 207 | 0.030 |
Why?
|
| Software | 1 | 2017 | 130 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 703 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 590 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2018 | 163 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2017 | 189 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 2 | 2008 | 57 | 0.030 |
Why?
|
| Recurrence | 2 | 2007 | 295 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 612 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2011 | 1910 | 0.030 |
Why?
|
| Models, Biological | 1 | 2017 | 432 | 0.030 |
Why?
|
| Disease Progression | 2 | 2011 | 633 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2010 | 1508 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2004 | 480 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2004 | 79 | 0.020 |
Why?
|
| Perfusion Imaging | 1 | 2012 | 8 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2011 | 31 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 111 | 0.020 |
Why?
|
| Minnesota | 1 | 2011 | 20 | 0.020 |
Why?
|
| Recovery of Function | 2 | 2003 | 251 | 0.020 |
Why?
|
| Echocardiography | 2 | 2004 | 202 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 200 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2010 | 23 | 0.020 |
Why?
|
| Endarterectomy, Carotid | 1 | 2010 | 29 | 0.020 |
Why?
|
| Thirst | 1 | 2008 | 1 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2008 | 23 | 0.020 |
Why?
|
| Diuretics | 1 | 2008 | 28 | 0.020 |
Why?
|
| Drug Costs | 1 | 2009 | 51 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2009 | 51 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2008 | 24 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 755 | 0.020 |
Why?
|
| New Jersey | 1 | 2008 | 9 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 176 | 0.020 |
Why?
|
| Emergencies | 1 | 2008 | 47 | 0.020 |
Why?
|
| American Hospital Association | 1 | 2007 | 3 | 0.020 |
Why?
|
| Inflation, Economic | 1 | 2007 | 1 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2009 | 378 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 211 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2007 | 55 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2007 | 47 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 509 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 924 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 101 | 0.020 |
Why?
|
| Oleic Acids | 1 | 2004 | 9 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 138 | 0.010 |
Why?
|
| Embolism | 1 | 2003 | 8 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2004 | 208 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 508 | 0.010 |
Why?
|
| Maryland | 1 | 2003 | 28 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 150 | 0.010 |
Why?
|
| Diffusion | 1 | 2003 | 17 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 310 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 3801 | 0.010 |
Why?
|
| Perfusion | 1 | 2003 | 77 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 438 | 0.010 |
Why?
|
| Critical Pathways | 1 | 2003 | 52 | 0.010 |
Why?
|
| Myocardium | 1 | 2004 | 199 | 0.010 |
Why?
|
| Heart | 1 | 2004 | 191 | 0.010 |
Why?
|
| Triage | 1 | 2003 | 76 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 259 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2003 | 239 | 0.010 |
Why?
|
| Blood Volume | 1 | 2001 | 9 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 2001 | 33 | 0.010 |
Why?
|
| Causality | 1 | 2001 | 38 | 0.010 |
Why?
|
| Demography | 1 | 2001 | 112 | 0.010 |
Why?
|
| Age Factors | 1 | 2004 | 1262 | 0.010 |
Why?
|
| Brain Stem Infarctions | 1 | 1999 | 2 | 0.010 |
Why?
|
| Cerebral Arterial Diseases | 1 | 1999 | 2 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2003 | 1607 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2004 | 657 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1999 | 124 | 0.010 |
Why?
|
| Incidence | 1 | 2001 | 1289 | 0.010 |
Why?
|